LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Elenco Azioni・Gilead Sciences Inc.

Gilead Sciences Inc.

Chiusa

SettoreSettore sanitario

129.48 0.26

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

128.92

Massimo

130.03

Metriche Chiave
By Trading Economics
Entrata	-162M 2B
Vendite	-965M 7B
P/E Media del settore	17.837 49.888
EPS	2.03
Rendimento da dividendi	2.37
Margine di Profitto	29.037
Dipendenti	17,000
EBITDA	1.2B 3.5B

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+23.96% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	2.37% 2.38%
Utili prossimi	6 ago 2026
Prossima data del Dividendo	29 giu 2026
Prossima data del' Ex Dividendo	15 giu 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-1.9B 163B
Apertura precedente	129.22
Chiusura precedente	129.48

Notizie sul Sentiment di mercato

By Acuity

18%

82%

22 / 344 Classifica in Healthcare

Gilead Sciences Inc. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 mag 2026, 20:49 UTC

Utili

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

7 apr 2026, 14:24 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update

7 apr 2026, 12:53 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

4 giu 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

8 mag 2026, 08:10 UTC

Utili

Gilead Stock Falls After Earnings. A Big Acquisition Spree Is Coming at a Cost. -- Barrons.com

8 mag 2026, 08:08 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mag 2026, 22:33 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mag 2026, 21:09 UTC

Utili

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7 mag 2026, 20:51 UTC

Utili

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7 mag 2026, 20:06 UTC

Utili

Gilead Sciences Raises 2026 View To Sales $30B-$30.4B >GILD

7 mag 2026, 20:05 UTC

Utili

Gilead Sciences Sees 2026 Adj Loss/Shr 65c-Adj Loss/Shr $1.05 >GILD

7 mag 2026, 20:05 UTC

Utili

Gilead Sciences Sees 2026 Loss/Shr $2.85-Loss $3.25 >GILD

7 mag 2026, 20:02 UTC

Utili

Gilead Sciences: Biktarvy Sales Increased 7% Yr-Over-Yr to $3.4B >GILD

7 mag 2026, 20:01 UTC

Utili

Gilead Sciences 1Q Rev $6.96B >GILD

7 mag 2026, 20:01 UTC

Utili

Gilead Sciences 1Q Adj EPS $2.03 >GILD

7 mag 2026, 20:01 UTC

Utili

Gilead Sciences 1Q Total Liver Disease Sales $767M >GILD

7 mag 2026, 20:01 UTC

Utili

Gilead Sciences 1Q EPS $1.61 >GILD

28 apr 2026, 12:45 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences Completes Acquisition Of Arcellx Ahead Of Potential Commercial Launch Of Anito-cel >GILD

17 apr 2026, 12:32 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences Extends Arcellx Tender Offer >GILD ACLX

17 apr 2026, 12:30 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Receives All Required Regulatory Approvals For The Acquisition Of Arcellx And Extends Tender Offer >GILD

7 apr 2026, 14:36 UTC

Acquisizioni, Fusioni, Takeovers

EQT Life Sciences: The Deal Is Expected to Close in 2Q of 2026

7 apr 2026, 14:35 UTC

Acquisizioni, Fusioni, Takeovers

EQT Life Sciences: Gilead Plans to Finance Transaction With Cash and Senior Unsecured Notes

7 apr 2026, 14:34 UTC

Acquisizioni, Fusioni, Takeovers

EQT Life Sciences: Gilead Will Also Buy TUB-030

7 apr 2026, 14:28 UTC

Acquisizioni, Fusioni, Takeovers

EQT Life Sciences to Exit Minority Stake in Tubulis via Sale to Gilead Sciences for Up to $5B

7 apr 2026, 14:23 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Gilead Buying Another Cancer-Drug Partner -- Market Talk

7 apr 2026, 13:55 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Gilead Continues Buying Spree with Tubulis Deal -- Market Talk

7 apr 2026, 13:14 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion -- Barrons.com

7 apr 2026, 12:30 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Finance Tubulis Deal With Cash on Hand, Senior Unsecured Notes >GILD

7 apr 2026, 12:30 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Tubulis Deal Antibody-Drug Conjugates on Oncology Pipeline >GILD

7 apr 2026, 12:30 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Tubulis Deal Includes Up to $1.85 Billion Contingent Milestone Payments >GILD

Confronto tra pari

Modifica del prezzo

Gilead Sciences Inc. Previsione

Obiettivo di Prezzo

By TipRanks

23.96% in crescita

Previsioni per 12 mesi

Media 160.11 USD 23.96%

Alto 180 USD

Basso 122 USD

Basato su 21 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Gilead Sciences Inc. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

21 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 21 che hanno fornito valutazioni azionarie a Gilead Sciences Inc. - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

22 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.